Arizona Biotech News

The Arizona Bioscience Experience in New Mexico

2008-06-25T08:54:00.001-07:00

Biotech News

The Arizona Bioscience Experience in New Mexico

Guest Speaker Robert Eaton,

President and CEO of Arizona Bio

"The Arizona Bioscience Experience" on July 8th

Bob Eaton serves as CEO of AZ Bio, the Ariziona Bioindustry Association which he joined in October, 2007. During his short time with AZ Bio, Bob has already succesfully merged the State's regional bioscience groups into a single, strong Statewide association, and has begun an aggressive drive to expand membership.

Previously, Bob served for ten years as president of MdBio where he expanded the nonprofit organization from a staff of two to eight with an annual operating budget of about $2 million. He managed the investment of approximately $4 million in more than 30 bioscience companies, and has worked closely with senior biotechnology and pharmaceutical industry leaders regarding state and federal regulatory and policy issues. Under his leadership, MdBio developed an array of programs to support the growth andsuccess of bioscience companies, primarily in theareas of business development, communication, workforce training, and K-12 education.

In previous roles, Eaton worked with the Technology Council of Maryland, where he worked with industry leaders to establish the Maryland Bioscience Alliance; served as director of R&D programs for the Pharmaceutical Manufacturers Association (now PhRMA) in Washington, D.C.; worked with a small molecular biology services company; and was involved in protein biochemistry research at the National Institutes of Health.

Eaton also served on several boards and councils in Maryland and Virginia related to the bioscience and technology industries. He received a master's degree in science, technology, and public policy from George Washington University and a bachelor's degree in applied and engineering physics from Cornell University.

NMBio July Meeting: Bob Eaton of AZ Bio
Date: Tuesday, July 8th, 2008
UNM STC Rotunda
11:30 am to 1:00 pm
Cost: $25.00 NMBBA Members
$35.00 Non-Members

RSVP to Annie Hooten at anniehooten@aol.com
by Friday Noon, July 4th, 2008 or register using the PayPal links above.

Prepayment is required by either check or credit card (M/C or VISA only) to reserve. Send checks to NMBio, P.O. Box 80233, Albuquerque, NM 87198
AZhttp, Inc.
Biotechnology Marketing

State-of-the-Art Biotechnology Equipment Hits the Auction Block

2008-06-14T19:49:00.000-07:00

Biotech News
AZhttp, Inc.

State-of-the-Art Biotechnology Equipment Hits the Auction Block

Cowan Alexander ramps up for live webcast equipment auction for Nucleonics and Amphora Discovery.

June 13, 2008 -- Cowan Alexander, LLC a leading biotechnology equipment auctioneer, today announced two Live Global Webcast equipment auctions. The first auction will take place Tuesday, June 17, 2008 at 11 a.m. EDT at Nucleonics in Horsham, PA; the second auction will take place Thursday, June 24, 2008 at 11:00 a.m. EDT at the Amphora Facility in Durham, NC. Equipment can be inspected the day prior at the respective facilities from 9 a.m. to 4 p.m. and the morning of the sale.

Equipment highlights from the Nucleonics sale include Gentinge 533LS vacuum/gravity sterilizers, Bioflow 3000 fermentor, Li-Cor Odyssey imaging system, Waters Alliance HPLC's, Berthold Centro XS3 luminometer, Microbiology System V.95 autoclave, Applied Biosystems 7500 PCR, Baker biosafety cabinets, assorted incubators and freezers, Sorvall and Eppendorf centrifuges, Molecular Devices SpectraMax 2 plate readers, Leica tissue prep and processing instrumentation, Olympus IMT-2 and IX71 microscopes, Pelicon 2 TFF and many more items. The Amphora Discover sale includes at Large Quantity of Caliper 250, Labchip 3000, Sciclone ALH3000 and Molecular Devices Ion Works HT liquid assay workstations plus general purpose lab support equipment, IT gear, facility equipment, office equipment and furniture and much more.

These auctions represent a tremendous buying opportunity for companies both large and small looking for quality equipment at auction price. All equipment will be sold regardless of price with no minimum bid and no reserve prices
"These auctions represent a tremendous buying opportunity for companies both large and small looking for quality equipment at auction price. All equipment will be sold regardless of price with no minimum bid and no reserve prices," said Don Cowan, president of Cowan Alexander.
The auction will also be broadcast live on the Internet, prospective buyers may bid live onsite or real-time on the web. For more information please visit www.cowanalexander.com.

About Cowan Alexander LLC
Cowan Alexander LLC is the nation's leading technology auction, capital recovery and valuation company. Cowan Alexander provides custom-tailored asset disposition and valuation services to technology investors, lenders and technology companies. This experienced team of professionals has successfully sold more than $1 billion in assets and has completed more than 1,000 valuation assignments worldwide. For more information, visit www.cowanalexander.com.

Biotechnology Marketing

Leading U.S. Bioscience Pioneers Enter International Collaboration with Government of Luxembourg to Accelerate Biomedical Research

2008-06-07T12:49:00.000-07:00

Biotech News
AZhttp, Inc.

Leading U.S. Bioscience Pioneers Enter International Collaboration with Government of Luxembourg to Accelerate Biomedical Research

International Public-Private Initiative to Drive Innovation in the U.S. and Overseas

06-05-2008

New York, June 6, 2008 - Three of the United States' most prominent biomedical science leaders have been tapped by the government of Luxembourg for an unprecedented international collaboration to establish a bioscience center of excellence in the heart of the European Union.
The government of the Grand Duchy of Luxembourg has announced an ambitious plan to increase the pace of innovation based on cutting-edge research in the areas of molecular biology, systems biology and personalized medicine. The initiative will include formation of a centralized biobank/tissue repository, two major projects to further research in the field of molecular biology, which is the cornerstone of personalized medicine, and a project to demonstrate the effectiveness of new diagnostics tests for earlier detection and treatment of lung cancer.

The U.S. organizations involved in the collaboration are: The Partnership for Personalized Medicine (PPM) led by Dr. Leland H. Hartwell, director, Nobel Laureate in Physiology or Medicine in 2001 and president of the Fred Hutchinson Cancer Research Center in Seattle, Washington; The Institute for Systems Biology (ISB), also in Seattle, led by Dr. Leroy Hood, president of ISB and co-founder of U.S.-based Amgen Inc.; and Arizona's Translational Genomics Research Institute (TGen), led by Dr. Jeffrey Trent, president and scientific director of TGen and former scientific director at the National Human Genome Research Institute of the National Institutes of Health.

The announcement was made jointly by three branches of Luxembourg's government, the Ministry of the Economy and Foreign Trade, the Ministry for Culture, Higher Education and Research and the Ministry of Health. The Luxembourg government is investing $200 million in the initiative, with the hope that ultimately it will improve the health of its own people by increasing the ability to administer the right drug to the right patient at the right time and in the right dose. In addition, it seeks to accelerate the global pace and integration of biomedical research, education and commercial development around the world.

The public-private initiative is expected to serve as a model for other international collaborations among partners looking to not only share research and development costs but also to gain access to each other's information, networks and markets. The Luxembourg collaboration was developed and negotiated in consultation with the global professional services organization, PricewaterhouseCoopers, and is built on an integrated approach that links research, education, healthcare and the economy.

The collaboration consists of three interrelated research initiatives that build on each other. They include:

Build the Integrated BioBank of Luxembourg (IBBL)
Led by TGen, Luxembourg will launch the Integrated BioBank of Luxembourg, which has the promise of becoming a premier European hub for advanced biobanking, biotechnology and biomedical informatics.

Biobanks are invaluable in bridging the gap between the pace of scientific and technological advancement and translation to clinical benefit. Most existing European and U.S. biobanks focus on simple collection and redistribution of specimens to scientists and educators. The IBBL will implement uniform standards for collection, storage and redistribution of an anticipated full range of tissue samples (e.g. blood, serum and tumor tissue). However, the added value of this next-generation biobank will be the detailed, centralized, molecular-based characterization of biospecimens, which over time (and ultimately linked to detailed clinical information) will lead to amassing an extensive database of medically relevant information.

The project will unite and leverage expertise in biology, pathology, informatics and information technology infrastructure, laboratory operations, transportation, legal matters and ethics.

Accessible to European and international colleagues, IBBL will maintain its collection of tissues in a research environment that will seek collaborations broadly within the wider research community. As such, the IBBL will serve as a centralized resource for sharing and comparing research results through a robust, scalable and secure bioinformatics system that supports the collection, processing, storage, annotation and distribution of biospecimens and data.

TGen's principal role working with Luxembourg scientists and physicians, will be to jointly develop and implement the next generation of molecular medicine through the development of the information architecture and technology implementation.

Create the Center for Systems Biology Luxembourg (CSBL)
The Institute for Systems Biology will collaborate with the University of Luxembourg to create the Center for Systems Biology Luxembourg. The Center will participate with ISB on two basic research projects designed to provide greater insight into the identification of disease and to enable more effective treatments:

ISB Research Project 1: The first project will include completion of a personalized human genome sequencing map on a minimum of one hundred subjects and development of new methods for understanding the role of genetic variations in disease, leading to new insights into diagnosis, treatment and prevention.
ISB Research Project 2: The second project is development of integrated systems proteomics, RNA and cell analysis methodology and tools based on ISB’s groundbreaking discovery of protein blood "fingerprints" and single-cell characteristics that can report on the physiological state of the body's 50 major organs. The research promises to lead to powerful early diagnostic approaches to not only treat but also predict disease and the ability to monitor the effects of existing drugs, including both effective responses or adverse reactions.
ISB's role will be to apply its systems biology approaches and tools to study model organisms such as mice to determine how best to interrogate and analyze human genetic data at the DNA sequence level. New computational and mathematical tools will be developed to facilitate these large-scale genome analyses and to integrate these insights with protein blood fingerprints.
Launch the Luxembourg Project Lung Cancer
The goal of Luxembourg Project Lung Cancer is to advance research in personalized medicine by pursuing research projects to develop molecular diagnostics for specific disease. These research projects center on the selection and validation of biomarkers to more effectively diagnose and manage disease from early detection through therapeutic follow-up.

The Luxembourg project will focus specifically on lung cancer for which there are no reliable tools for early detection and for patients with advanced disease with virtually no known cures. The project also will seek to demonstrate that earlier detection and intervention can reduce healthcare costs. The initiative capitalizes on the efforts of the U.S.-based Partnership for Personalized Medicine (PPM), led by Dr. Hartwell, and will develop use of new personalized, protein-based diagnostic tools.

The Partnership will unite the efforts and capabilities of investigators at TGen and the Biodesign Institute at Arizona State University, as well as the Fred Hutchinson Cancer Center in Seattle. Over time this effort is expected to link to a host of other research institutions and initiatives in the U.S. and beyond.

Personalized medicine focuses on improved prevention, targeted screening, early diagnosis and treatment of the causes of illness with drugs based on an individual's genetic and biological make-up, such as drugs targeted and suited to each patient. It is believed that personalized medicine will gradually take the place of conventional medicine. Ultimately, this will result in great improvements in the ability to administer the right drug to the right patient at the right time and in the right dose.

About the Institute for Systems Biology
Founded in 2000, the Institute for Systems Biology (ISB) is an internationally renowned, non-profit research institute headquartered in Seattle and dedicated to the study and application of systems biology. Founded by Leroy Hood, Alan Aderem and Ruedi Aebersold, ISB seeks to use systems methods to unravel the mysteries of human biology and identify strategies for predicting and preventing diseases such as cancer, diabetes and AIDS. ISB's systems approach integrates biology, computation and technological development, enabling scientists to analyze all elements in complex biological systems rather than one gene or protein at a time. For more information about ISB, visit www.systemsbiology.org.

About the Partnership for Personalized Medicine
The Partnership for Personalized Medicine is a major healthcare research initiative that unites contributions from two leading Arizona-based philanthropic organizations: the Virginia G. Piper Charitable Trust and the Flinn Foundation with leadership and research capabilities from Fred Hutchinson Cancer Research Center, the Translational Genomics Research Institute and the Biodesign Institute at Arizona State University.

About Fred Hutchinson Cancer Research Center
At Fred Hutchinson Cancer Research Center, interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Hutchinson Center researchers, including three Nobel Laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, visit www.fhcrc.org.

About the Biodesign Institute at Arizona State University
The Biodesign Institute at ASU integrates diverse fields of science to cure and prevent disease, overcome the limitations of injury, renew the environment and improve national security. By fusing research in biology, engineering, medicine, physics, information technology and cognitive science, the institute accelerates discoveries into uses that can be adopted rapidly by the private sector. For more information, visit www.biodesign.asu.edu.

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process.

Biotechnology Marketing

TGen Researcher Receives the Young Investigator Award from the Arizona Alzheimer’s Consortium

2008-06-03T13:22:00.000-07:00

Biotech News
AZhttp, Inc.

TGen Researcher Receives the Young Investigator Award from the Arizona Alzheimer’s Consortium

Dr. Matthew Huentelman honored for his contributions to Alzheimer's disease and aging research

06-03-2008

PHOENIX, AZ, JUNE 3, 2008--Dr. Matthew Huentelman, an Associate Investigator in the Neurogenomics Division at the Translational Genomics Research Institute (TGen), was the recipient of the Young Investigator Award from the Arizona Alzheimer’s Consortium. Dr. Huentelman was recognized for his pioneering accomplishments in Alzheimer’s disease research and for being an outstanding mentor to his research team and students.
"The Arizona Alzheimer's Consortium is extremely proud of Matt. He has already made significant contributions to the genetic understanding of memory and Alzheimer's disease, and to the discovery of promising memory-enhancing treatments. Matt's know-how and accomplishments, his dedication, hard work and enthusiasm, and his mentoring skills and collaborative spirit are examples for us all," said Dr. Eric Reiman, Director, Arizona Alzheimer's Consortium.

The Young Investigator Award is given annually to a young investigator in Arizona for their contributions to Alzheimer's disease and aging research. The selection process for the Young Investigator Award is extremely competitive. Each candidate is evaluated by the Arizona Alzheimer's Consortium's Internal Scientific Advisory Board, which consists of 25 researchers from the organization's seven institutional members.

"I really value my relationship with the Arizona Alzheimer's Consortium. There are many excellent young investigators within the Consortium, and I consider it a great honor to receive this award,” said Dr. Huentelman.

Dr. Huentelman received a plaque and a $5,000 research grant to continue his work in memory research. He accepted the award at the Consortium's annual meeting attended by fellow researchers, members of the community, the Consortium's Internal and External Advisory Boards, and the meeting's keynote speaker, Dr. David Holtzman, the Andrew B. and Gretchen P. Jones Professor and Chairman of the Department of Neurology at the Washington University School of Medicine.

"This is an outstanding honor for a terrific young scientist whose efforts are moving this field forward in remarkable ways,” said TGen President Dr. Jeffrey Trent.

Currently, Dr. Huentelman is using genetic technologies to study a gene called KIBRA, which plays a significant role in memory performance in humans. Dr. Huentelman has received grants from the National Institutes of Health and Science Foundation Arizona to continue this work with the hope of developing promising new Alzheimer's disease treatments.

Dr. Huentelman joined TGen in July of 2004 after completing his doctoral work at the University of Florida's Department of Physiology and Functional Genomics where he investigated the application of gene therapy in the study of hypertension. His undergraduate degree is from Ohio University's Department of Chemistry and Biochemistry. Dr. Huentelman's career includes visiting researcher stints in Moscow, Russia at the prestigious Lomonosov Moscow State University and in the United Kingdom at the University of Bristol. At present time he has published over 25 peer-reviewed manuscripts in the scientific literature.

The Arizona Alzheimer's Consortium is the nation’s leading model of statewide collaboration in Alzheimer's disease research. Established in 1998, the Consortium capitalizes on its participating institutions' complementary strengths in brain imaging computer science, genomics, the basic and cognitive neurosciences and clinical and neuropathology research to promote the scientific understanding and early detection of Alzheimer's disease and find effective disease-stopping and prevention therapies. It also seeks to educate Arizona residents about Alzheimer's disease, research progress in the state and the resources needed to help patients, families and professionals manage the disease. The Consortium is determined to find effective treatments to halt the progression and prevent the onset of Alzheimer's disease in the next 12 years

# # #

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen's vision is of a world where an understanding of genomic variation can be rapidly translated in a manner tailored to individual patients.

About the Arizona Alzheimer's Consortium
The Arizona Alzheimer's Consortium is a 501(c)(3) organization that includes the state-supported Arizona Alzheimer's Research Center (AARC), the National Institute on Aging (NIA)-funded Arizona Disease Core Center (Arizona ADCC), and independently funded research programs. Its seven member institutions include: Arizona State University, the Barrow Neurological Institute, the Mayo Clinic Arizona, the Sun Health Research Institute, the Translational Genomics Research Institute (TGen), the University of Arizona, and the Banner Alzheimer's Institute. Its three affiliated institutions include Banner Good Samaritan Medical Center, the Southern Arizona Veterans Administration Health Care System and the University Physician's Hospital at Kino.

Biotechnology Marketing

Researchers close in on new melanoma gene

2008-05-23T23:21:00.001-07:00

Biotech News

Researchers close in on new melanoma gene

Genome-wide study rapidly scans DNA for clues, narrows search

05-18-2008

Phoenix, Arizona and Queensland, Australia -- It has long been known that prolonged exposure to the suns harmful UV rays can lead to Melanoma, the deadliest form of skin cancer. An unanswered question, however, is why some people are more likely to develop melanoma than others. Despite years of research and clinical development, melanoma incidences continue to rise around the world. According to the National Cancer Institute, the percentage of people in the United States who develop melanoma each year has more than doubled in the past 30 years.

Results published today from a study led by researchers from The Translational Genomic Research Institute (TGen) in Phoenix, Arizona and The Queensland Institute of Medical Research (QIMR), Queensland, Australia, however, may yet change these statistics. The team is close to discovering a new gene that could help explain variation in melanoma risk.

In a report appearing in an Advance Online Publication (AOP) of the journal Nature Genetics, the researchers and their colleagues identify a region on chromosome 20 (20q11.22) that influences a person’s risk of developing melanoma.

According to Dr Kevin Brown, TGen Investigator and the paper's co-first author, compared to other genetic research focusing on familial (or inherited) cases of melanoma, this finding holds implications for the general population

"We're closing in on genetic variants which cause 16 percent of the population to be at nearly double the increased risk of developing the disease. In public health terms, this finding is highly significant," Dr. Brown said.

The researchers narrowed the gene location through a genome-wide association study - a first in melanoma research. Genome-wide studies involve rapidly scanning DNA of many people to find genetic variations associated with a particular disease. After identifying new genetic associations, researchers can use the information to develop better strategies to detect, treat and prevent the disease.

"The aim of our work is to identify and understand the genetic factors influencing melanoma so we can better predict risk estimates," said QIMR's Dr. Stuart MacGregor, co-first author on the study. "This in turn, means people will be better informed and can take the right precautions to avoid developing this increasingly common cancer."

How The Study Works
A genome-wide association study involves scanning the DNA from two sets of individuals: those with a particular disease (cases) and those of similar individuals without the disease (controls). The DNA of each sample then undergoes examination for strategically selected markers of genetic variation, called single nucleotide polymorphisms, or SNPs. If certain genetic variations are found to be significantly more frequent in people with the disease compared to people without disease, those variations are said to be "associated" with the disease. The associated genetic variations can serve as roadmaps to the region of the human genome where the disease-causing gene resides.

The study - whose data collection began 20 years ago - involved more than 4,000 Australian samples (2,019 cases and 2,105 controls) and was a joint project between Australian, American and European research groups.

About Melanoma
According to the National Cancer Institute's on-line booklet, What You Need to Know About Melanoma, melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.

Melanoma is the most serious type of cancer of the skin. Each year in the United States, more than 64,800 people learn they have melanoma and approximately 8,400 will die from the disease. The disease is particularly prevalent in the Southwest, particularly Arizona, where the incidence rate is double the national average and is becoming more common every year.

Funding
Funding for Dr. Browns lab was provided by Melanoma Research Foundation (MRF) Research Grant Program, whose purpose is to support promising medical research that will further the goal of developing an effective treatment and possible cure of malignant melanoma, while encouraging scientists and clinicians to join in this mission. The Foundation funds both junior and senior researchers. In both grant programs, emphasis will be placed on projects that explore innovative approaches to understanding melanoma and its treatment. Both basic and clinical research projects will be considered.

"Each year, we receive grant requests from some of the best and brightest melanoma researchers in the world," said Linda Pilkington, Executive Director, Melanoma Research Foundation. "The research conducted by scientists like Dr. Brown gives melanoma patients the hope they need and deserve - hopefully one day leading to a cure for this deadly disease."

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen's vision is of a world where an understanding of genomic variation can be rapidly translated in a manner tailored to individual patients.

About QIMR
Established in 1945 by the Queensland Government, The Queensland Institute of Medical Research (QIMR) is one of the largest medical research institutes in the southern hemisphere, and is recognised worldwide for the quality of its research. Originally established to further the study of tropical diseases in North Queensland, QIMR has, over its 60 years' history, broadened its scope to include the immunological, biological and molecular basis of a wide range of infectious diseases, cancers and other disorders. QIMR has also built a strong research stream in epidemiology, the study of the environmental, lifestyle and genetic factors that contribute to disease incidence among populations.

About the Melanoma Research Foundation
The Melanoma Research Foundation (MRF) is the largest private, national organization devoted to melanoma in the United States. The Foundation is committed to the support of medical research in finding effective treatments and eventually a cure for melanoma. The Foundation also educates patients and physicians about prevention, diagnosis and treatment of melanoma, while acting as an advocate for the melanoma community to raise awareness of this disease and the need for a cure. The MRF Web site is the premiere source for melanoma information seekers. More information is available at www.melanoma.org.

AZhttp, Inc.
Biotechnology Marketing

Webby Awards marks ‘Planet Bob’ video with ‘Official Honoree’ distinction

2008-04-22T12:04:00.000-07:00

Webby Awards marks ‘Planet Bob’ video with ‘Official Honoree’ distinction

TEMPE, Ariz. – The Webby Awards, the leading international honor for the Web, recently cited “Planet Bob” as an Official Honoree, a distinction that recognizes work exhibiting remarkable achievement. “Planet Bob,” a joint video production from Arizona State University’s International Institute for Species Exploration and Media Alchemy, Inc., uses humor to draw attention to the serious subject of biodiversity and the science of taxonomy. Combining live action, state-of-the-art animation, and the vocal talents of venerable TV host Hugh Downs and others, “Planet Bob” presents the mysterious, exciting – and surprisingly funny – side of taxonomy.

Hailed as the "Oscars of the Internet" by the New York Times, the Webby Awards is the leading international award honoring excellence on the Internet, including Web sites, interactive advertising, online film and video, and mobile Web sites.

"The Webby Awards honors the outstanding work that is setting the standards for the Internet," said David-Michel Davies, executive director of the Webby Awards. "The Official Honoree selection for ’Planet Bob’ is a testament to the skill, ingenuity and vision of its creators.”

“The ‘Planet Bob’ video was a great team effort between ASU and Media Alchemy,” said Erik Holsinger, executive producer and president of Media Alchemy. “Dean Quentin Wheeler gave us a wonderful opportunity to use comedy to effectively explore both a very serious environmental issue and a complex science.”

“The Web site www.PlanetBob.asu.edu and the video ‘Planet Bob’ represent new ways to present taxonomy and biodiversity, in a creative fusion between academia and popular technology,” said Wheeler, ASU vice president and dean of the College of Liberal Arts and Sciences. Professor Wheeler also is the founding director for the International Institute for Species Exploration (species.asu.edu).

The 12th annual Webby Awards received nearly 10,000 entries from more than 60 countries and all 50 states. Out of the more than the 10,000 entries submitted, fewer than 15 percent received this honor and were deemed an Official Honoree. The awards are judged by the International Academy of Digital Arts and Sciences, a global organization that includes David Bowie, Harvey Weinstein, Arianna Huffington, Matt Groening, Jamie Oliver, Vinton Cerf and RealNetworks CEO Rob Glaser.

Biotech News
AZhttp, Inc.
Biotechnology Marketing

Two New Therapies Show Promise for Cancer Patients

2008-04-22T11:42:00.000-07:00

Two New Therapies Show Promise for Cancer Patients

Clinical trial data and cutting-edge testing give key insights in the fight
against basal cell carcinoma and pancreatic cancer.

San Diego and Phoenix-April 15, 2008-Clinical researchers at Scottsdale
Healthcare and TGen today announced the results of two clinical trials that
show promise for patients battling cancer.

The Phase I clinical trial findings, presented at the this weeks Annual
Meeting of the American Association for Cancer Research by Daniel Von Hoff,
MD, FACG, focused on basal cell carcinoma (BCC) and pancreatic cancer. The
Arizona trials were conducted at TGen's Clinical Research Service (TCRS) at
Scottsdale Healthcare, a strategic alliance between TGen and Scottsdale
Healthcare's Clinical Research Institute.

Basal Cell Carcinoma In the first trial, a novel molecule, GDC-0449, shrinks
tumors in basal cell carcinoma (BCC) while having limited side effects,
including a loss of sense of taste, and a small amount of hair loss and
weight loss, suggesting a viable new treatment option. GDC-0449 works by
blocking a pathway - a series of chemical reactions within a cell- known as
Hedgehog, containing two genes (PTCH and SMO) that lead to a known
tumor-promoting gene called GLI1. Alterations in any of these genes have
been shown to lead to basal cell carcinoma and other diseases. GDC-0449 is a
chemical synthetic designed to replicate the properties of cyclopamine, a
chemical found in nature.

"Basal cell carcinoma affects about one million people a year and a
proportion of these patients have disease that is not curable with surgery.
We currently do not have any treatments that can effectively slow tumor
growth in these advanced patients. This finding has potential importance in
this population," said Daniel D. Von Hoff, M.D., Physician in Chief at the
Translational Genomics Research Institute (TGen) and Chief Medical Officer
for the Scottsdale Clinical Research Institute at Scottsdale Healthcare.

Typically diagnosed with a simple biopsy, the risk of BCC increases for
those individuals with a family history, or prolonged exposure to
ultraviolet (or UV) rays from the sun. While BCC has an extremely low rate
of metastasis, it can lead to scarring and disfigurement if left untreated.

The trial results showed durable clinical benefit -defined as tumor
shrinkage visible on X-ray or other physical exam or improvement in symptoms
without tumor growth- was observed in eight out of the nine patients
evaluated.

The first patient treated in the trial has shown clinical improvement for
approximately 450 days and is ongoing, Von Hoff says, with almost no side
effects beyond minimal hair loss.

"He came to us short of breath and in pain, but he has had a very dramatic
response with this drug," Von Hoff said.

Further evaluations of the study participants measured the presence of GLI1
in skin cells sampled from the participants. Among all patients tested to
date, there was reduction in this marker, indicating that the drug was
affecting the hedgehog pathway.

The trial, sponsored by Genentech, also included clinical sites at the
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University,
Baltimore, Maryland and Karmanos Cancer Institute, Detroit, Michigan.

Pancreatic Cancer In the second trial, Von Hoff and colleagues showed that a
novel combination of two drugs (nanoparticle albumin-bound paclitaxel, or
"nab-pacilitaxel" and gemcitabine) showed a significant clinical benefit in
more than 80 percent of pancreatic cancer patients. "Unfortunately, most
patients with pancreatic cancer have a very poor survival, and until now,
the only option has been gemcitabine alone or in combination with
erlotinib," said Von Hoff.

The researchers utilized the Target NowT tumor profiling analysis, a
cutting-edge oncology testing service performed by Caris Dx and Caris MPI,
to better understand the characteristics expressed in patient's tumors. In
this ongoing research program, Von Hoff and colleagues found the SPARC
(Secreted Protein Acidic and Rich in Cysteine) protein to be commonly found
in pancreatic cancer specimens. The SPARC protein is being investigated by
Abraxis BioScience in this trial as a potential target for nab-paclitaxel. A
test for SPARC, developed at Abraxis and Caris MPI and applied by Caris MPI
under contract with Abraxis, was utilized to analyze SPARC in the pancreatic
cancer patients in the trial.

The finding of SPARC protein in pancreatic cancer patients, also described
by other investigators, was the basis for this phase I clinical trial that
Von Hoff presented at AACR.

"Chemotherapy often means combining more than one drug, and we do not want
to just take the next thing off the shelf. We want to know as much about a
tumor as possible going in," Von Hoff said.

Researchers reported on the first 20 patients of what will eventually be a
42-patient trial.

"This was a phase I trial, and phase I trials are usually designed to test
safety, hoping it will also determine efficacy. The fact that we saw this
kind of activity in a phase I trial is dramatic," Von Hoff said.

"The rationale behind the combination of Gemcitabine plus Abraxane was based
on careful science and was designed and executed by some of the leading
experts in pancreas cancer in the world. While the data is preliminary and
longer follow-up will be important, the biochemical and radiographic
responses look very encouraging", says Dr. Laheru of Johns Hopkins Kimmel
Cancer Center.

The trial, sponsored by Abraxis BioScience, also included clinical sites at
South Texas Oncology and Hematology, P.A., San Antonio, Texas, University of
Alabama at Birmingham, Birmingham, Alabama, and the Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins University, Baltimore,
Maryland.

About Abraxis BioScience Abraxis BioScience is a fully integrated global
biotechnology company dedicated to the discovery, development and delivery
of next-generation therapeutics and core technologies that offer patients
safer and more effective treatments for cancer and other critical illnesses.
The company's portfolio includes the world's first and only protein-bound
nanoparticle chemotherapeutic compound (ABRAXANE), which is based on the
company's proprietary tumor targeting technology known as the nabT platform.
The first FDA approved product to use this nabT platform, ABRAXANE, was
launched in 2005 for the treatment of metastatic breast cancer. Abraxis
trades on the NASDAQ Global Market under the symbol ABBI. For more
information about the company and its products, please visit
http://www.abraxisbio.com/.

About Caris Caris Dx provides world-class surgical pathology services to
physicians who treat patients in an ambulatory setting. The company provides
academic-caliber medical consults through its industry-leading team of
subspecialty fellowship and expert-trained pathologists in gastrointestinal
and liver pathology, hematopathology and dermatopathology. Caris Diagnostics
provides the highest levels of service to its customers and their patients
through its state-of-the-art laboratories; proprietary, advanced clinical
and technology solutions; and rigorous quality assurance programs.

Caris MPI is a leading molecular diagnostic company that provides
world-class genomic and proteomic analysis in the field of oncology and
other complex diseases. Caris MPI translates the latest discoveries made in
the research lab to patient care. Furthermore, the Tissue Banking and
Analysis Center (TBAC) at Caris MPI assists pharmaceutical companies and
researchers in their clinical trials for tissue procurement, preservation of
key analytes for cutting edge genomic and proteomic analysis and reporting
by CMPI.

About Scottsdale Healthcare Scottsdale Healthcare's vision is Setting the
Standard for Excellence in Personalized Healthcare. Established in 1962,
Scottsdale Healthcare is the not-for-profit parent organization of the
Scottsdale Healthcare Osborn, Scottsdale Healthcare Shea and Scottsdale
Healthcare Thompson Peak hospitals, Virginia G. Piper Cancer Center,
Scottsdale Clinical Research Institute, Scottsdale Healthcare Home Health
Services and Scottsdale Healthcare Community Health Services. Based in
Scottsdale, Arizona, Scottsdale Healthcare is governed by a volunteer board
of directors composed of leading local citizens. http://www.shc.org/

About TGen The Translational Genomics Research Institute (TGen) is a
non-profit 501(c)(3) organization dedicated to conducting groundbreaking
research with life changing results. Research at TGen is focused on helping
patients with diseases such as cancer, neurological disorders and diabetes.
TGen is on the cutting edge of translational research where investigators
are able to unravel the genetic components of common and complex diseases.
Working with collaborators in the scientific and medical communities, TGen
believes it can make a substantial contribution to the efficiency and
effectiveness of the translational process. TGen's vision is of a world
where an understanding of genomic variation can be rapidly translated in a
manner tailored to individual patients. For more information about TGen,
please visit http://www.blogger.com/www.tgen.org.

Biotech News
AZhttp, Inc.
Biotechnology Marketing

Phoenix Arizona Diabetes Expo

2008-04-15T21:26:00.000-07:00

Phoenix Arizona Diabetes Expo

About 5000 attendees last year.

Phoenix Arizona Diabetes Expo

Diabetes Expo Phoenix - American Diabetes Expo

PHOENIX Arizona — On Saturday, April 26, 2008, the American Diabetes Association will once again host the free Diabetes Expo—an annual, one-day event showcasing the latest products and services for people affected by diabetes. This highly interactive Diabetes Expo event includes activities for people of all ages, including a fun Youth Zone with exciting activities and information for children with diabetes and their families. The Diabetes Expo also provides the public with a unique opportunity to talk with health care experts and obtain important medical and nutrition information.

“If you or a loved one has diabetes – or is at high risk of developing the disease – Diabetes Expo provides a fun, relaxed environment to learn a great deal about the important aspects of prevention and management of diabetes and its serious complications,” said Howard Shulman, DO, FACP, FACOI, Diabetes Expo Chair. “The Diabetes Expo is for all people affected by diabetes, as well as anyone interested in healthy eating and active living.”

Diabetes is the nation’s fifth deadliest disease, and it has no cure. In 2005, there were approximately 469,000 residents of Arizona who self-identified as having diabetes, nearly 7.5 percent of the total population (Behavior Risk Factor Surveillance Survey, 2005). Diabetes can lead to serious complications and premature death, but people with diabetes can take steps to manage the disease and lower the risk of complications. Early diagnosis and treatment of diabetes is critical. Unfortunately, many people living with diabetes do not even know it.

More than 75 exhibitors are participating in the 12th annual ADA Diabetes Expo in Phoenix, which will be held Saturday, April 26 from 8:30 a.m. to 3 p.m., at the Phoenix Convention Center, Halls F & G (33 S. Third St. in Phoenix, Arizona 85004). Admission is Free. Stop by “ADA World” and participate in interactive cooking demonstrations, live Web site demonstrations, and find out how the American Diabetes Association is helping people with diabetes and their families in your community.

For more information about diabetes or the Diabetes Expo, call 1-800-DIABETES (1-800-342-2383) or visit the Arizona Diabetes Expo site.

When: Saturday, April 26, 2008
Where: Phoenix Convention Center
Exhibit Halls F & G
33 S. Third St.
Phoenix, Arizona 85004 - Map and directions.

Time: 8:30 a.m. - 3:00 p.m.

The American Diabetes Association is the nation’s leading voluntary health organization supporting diabetes research, information and advocacy. Founded in 1940, the Association has offices in every region of the country, providing services to hundreds of communities.

Biotech News
AZhttp, Inc.
Biotechnology Marketing

Arizona Nanotechnology Cluster Symposium

2008-03-28T12:58:00.000-07:00

The 3rd Annual Arizona Nanotechnology Cluster Symposium

The Symposium will be held on Thursday, April 10, 2008 at the Scottsdale Community College Performing Arts Center, 9000 E Chaparral Rd, Scottsdale, AZ 85256. This will be an all day event with participation from local, national and international organizations. The theme for this year's event is "Small is Big: Global Perspectives on Nanotechnology". Local, National and International speakers to participate. We will also be awarding scholarships to middle school, high school and college students for furthering pursuits in nanotechnology.

Additionally on Friday, April 11 all participants are invited to a luncheon for the French Delegation Minalogic from Grenoble, France from 11 am- 1pm at the Tempe Center for the Arts, 700 W. Rio Salado Parkway, Tempe, AZ, 85281.

Speakers
Key Note Speaker: Brad Buswell, Deputy Under Secretary for Science and Technology, Department of Homeland Security

Speakers:
Dr. Stefan Zollner, Freescale Semiconductor, USA
Dr. Lerwen Liu, Zyvex, Singapore
Dr. Alain C. Diebold, Albany Nanotech, USA
Dr. Steve Goodnick, Arizona State University, USA
Dr. Narbeh Derhacobian, Adesto Technologies, USA
Dr. Papu Maniar, Motorola, USA
Nicolas Leterrier, Minalogic, Grenoble,France
Dr. Hao Yan, Arizona State University, USA
Dr. James Kolodzey, University of Delaware, USA
Dr. Debbie Stokes, FEI, Netherlands
Dr. Normand Voyer, Director, Laval University, Canada
Dr. Steffi Friedrichs, UK Nanotechnology Industries Association, UK
Dr. Max Lu, University of Queensland, Australia
Dr. Tom Picraux, CINT Los Alamos Labs, USA
Dr. Peter Mascher, McMaster University, Ontario, Canada

Panel Discussion: SBIR Funding Opportunities.
Moderator Brett Johnson Snell & Wilmer, Phoenix, AZ
Panelist:
John Waszczak, Raytheon, Tucson, AZ
Dr. John Lombardi, Ventana Research, Tucson, AZ
Dr. Matt Kim, QuantTera, Phoenix, AZ
Grant Anderson, Paragon Spaced Development Corp., Tucson, AZ

To Register please click on the link:
https://www.acteva.com/go/AZNANOTECH

The registration includes all the symposium materials, breakfast, lunch and evening reception.

Genome-wide Study Links Metabolic Changes With Early Onset of Alzheimer’s

2008-03-15T20:07:00.000-07:00

Genome-wide Study Links Metabolic Changes With Early Onset of Alzheimer’s
March 14 , 2008 by Editor
PHOENIX, AZ - Researchers at the Translational Genomics Research Institute (TGen) and their colleagues today report a finding that correlates significant under-expression of genes in certain brain regions with the pattern of metabolic deficits in the brains of individuals with Alzheimer’s. The findings provide new information surrounding the development of Alzheimer's disease and identify novel targets to consider when developing methods to diagnose and treat the disease. The results appear on-line in the Early Edition of the Proceedings of the National Academy of Sciences.

Alzheimer's disease is an irreversible, progressive disorder in which certain brain cells (called neurons) deteriorate, resulting in the loss of cognitive functions including memory, judgment and reasoning, movement coordination, and pattern recognition. In advanced stages of the disease, all memory and mental functioning may be lost. The progressive neurological disorder afflicts an estimated five million Americans, a number expected to triple by 2050.

more here: Genome-wide Study Links Metabolic Changes With Early Onset of Alzheimer’s

Bill Austin bill@azhttp.com http://www.azhttp.com/
Vice President of Business Development, AZhttp, Inc.
LinkedIn Profile: http://www.linkedin.com/in/billaustin

Biotech News
AZhttp, Inc.
Biotechnology Marketing

Sourcing and Negotiating Deals with Big BioPharma

2008-03-11T10:24:00.001-07:00

Sourcing and Negotiating Deals with Big BioPharma

A Panel & Networking Reception

Thursday March 20, 2008 @ the BioCenter

Agenda
3-3:30PM Networking, Registration, and Tour 3:30-5PM Panel 5-6:30PM St Patrick Networking Reception
From alliance to funding, Big Pharma and established biotech companies are increasingly investing in emerging companies. This Panel brings together executives from these larger companies to identify the type of deals now available to smaller companies, how to secure them, and how to manage them. Questions that will be raised include:• What are the best approaches for identifying a good partner?• What type of partnerships are commonly used? And is your company a best candidate for a simple license, or a full blown joint venture, or a M&A?• What about the rising of Big Pharma VC Funds?• What are the strategies for attracting, securing and structuring strategic investments?• How the Larger Bio-Companies’ needs differ from VCs’ needs?• What are the key contract terms to be negotiated?• What are the strategic reasoning behind different kinds partnerships?• Effects on existing and potential future collaboration partners and other strategic decisions.• Pros and cons of a small company partnering with a larger company.• “Dos” and “don’ts” of managing these important relationships

Speakers
• S. Edward Torres, Managing Director, Lilly Ventures
• Suzy Jones, Senior Director, Business Development, Genentech, Inc. • Sara M. Hall, Founder, Director & Chief Executive Officer, Tacere Therapeutics, Inc. • Mohan Iyer, Managing Director, Merchant Banking, Burrill & Company • David Summa, President & CEO, Acumen Pharmaceuticals • Lead Facilitator: Scott M. Iyama, Corporate Lawyer, Emerging Companies Group Member, Orrick, Herrington & Sutcliffe LLP

Click here for speakers' bios and to read more about this event. Cost & Registration Pre-register at http://www.acteva.com/booking.cfm?bevaid=151902
• Regular Price: $60• Partners' Network: $40• BioCenter Members: Free• On-site Registration: add $10 to the above (if space allows),

Biotech News
AZhttp, Inc.
Biotechnology Marketing

Global Biotechnology Markets Trends Report

2008-03-07T09:06:00.000-08:00

Biotech News
AZhttp, Inc.
Biotechnology Marketing

Global Biotechnology Markets Trends Report
"Global Biotechnology Markets Trends," a new research report published by Pharma-Reports.com, is an in-depth analysis of the cutting-edge developments in the global biotechnology markets.

Phoenix, AZ (PRWEB) February 21, 2008 -- "Global Biotechnology Markets Trends," a new research report published by Pharma-Reports.com, is an in-depth analysis of the cutting-edge developments in the global biotechnology markets:
http://pharma-reports.com/shop/item.asp?itemid=13&affillink=EPRW20080222

The report highlights the use of microorganisms, genetics, and biotech processes to create new and hi-tech methods to help developing countries prosper. Process descriptions, requirements, economics, challenges, regulatory frameworks, etc., are covered. The report examines the development of biotechnology in the developing regions of Africa, Asia, and Latin America. It also looks at what governments in these regions are doing to help the growth of this industry.

Various industrial uses of biotechnology are included in this report, with detailed description on how these processes can benefit countries and people in general. One such example is how to utilize the benefits of biotechnology to a waste management system. Many such innovative applications are included in this report, along with many more emerging trends in the biotechnology markets of the world today.

Other Topics covered in this report include:
Growing Importance of Therapeutic Proteins' Market in Biotechnology
Social and Economic Issues Facing the Development of Biotechnology
Recent Trends in Biotech R&D and Commercialization

Details on this report can be found at
http://pharma-reports.com/shop/item.asp?itemid=13&affillink=EPRW20080222

About the Publisher: "Global Biotechnology Markets Trends" is published by Pharma-Reports (www.Pharma-Reports.com), a pharmaceutical and biotechnology industry think tank and leading source for pharmaceutical and biotechnology industry information and research products. Details on all reports can be found at http://pharma-reports.com

Test post for new Arizona Biotech Site

2008-02-29T19:14:00.000-08:00

Biotech News
AZhttp, Inc.
Biotechnology Marketing

7th Annual North American Forum: Investing & Partnering in Biotech Business

2008-02-29T13:54:00.000-08:00

Wire (press release) - San Francisco,CA,USA Investors include MPM Capital,
HealthCare Ventures, Oxford Bioscience Partners, The Wellcome Trust, BB
Biotech Ventures, and Scottish Widows Investment ...

http://www.businesswire.com/news/google/20080222005132/en

See all stories on this topic:
http://news.google.com/news?hl=en&ncl=http://www.businesswire.com/news/goog
le/20080222005132/en

Biotech News
AZhttp, Inc.
Biotechnology Marketing

BIOTECH STOCKS Drug stocks mixed

2008-02-29T13:46:00.000-08:00

Lilly, Dynavax gain in early trading
MarketWatch - USA By Val Brickates Kennedy, MarketWatch BOSTON (MarketWatch)
-- Shares of Eli Lilly & Co. and Dynavax Technologies moved to higher ground
early Friday, ...

http://www.marketwatch.com/news/story/drug-stocks-mixed-lilly-dynavax/story
.aspx?guid=%7B8681DDB1-EF62-492B-9F0C-8BD484B90391%7D

See all stories on this topic:
http://news.google.com/news?hl=en&ncl=http://www.marketwatch.com/news/story
/drug-stocks-mixed-lilly-dynavax/story.aspx%3Fguid%3D%257B8681DDB1-EF62-492B
-9F0C-8BD484B90391%257D

Biotech News
AZhttp, Inc.
Biotechnology Marketing

Farmers in 12 developing countries look to biotech, critics ...

2008-02-28T08:34:00.000-08:00

High Plains Journal - Dodge City,KS,USA
SAN FRANCISCO (AP)--An industry-backed report says poorer countries have
adopted biotech farming like never before in another record year for
genetically ...

http://www.hpj.com/archives/2008/feb08/feb25/Farmersin12developingcountr.cf
m?login=true

See all stories on this topic:
http://news.google.com/news?hl=en&ncl=http://www.hpj.com/archives/2008/feb0
8/feb25/Farmersin12developingcountr.cfm%3Flogin%3Dtrue

Biotech News
AZhttp, Inc.
Biotechnology Marketing

Unapproved Biotech Traces Found In Corn Seed

2008-02-27T07:40:00.000-08:00

Unapproved Biotech Traces Found In Corn Seed - USDA CNNMoney.com - USA
WASHINGTON -(Dow Jones)- Dow AgroSciences has detected traces of an
unapproved biotech material in three lines of non-biotech corn seeds, the US
Department ...

http://money.cnn.com/news/newsfeeds/articles/djf500/200802221659DOWJONESDJO
NLINE000846_FORTUNE5.htm

See all stories on this topic:
http://news.google.com/news?hl=en&ncl=http://money.cnn.com/news/newsfeeds/a
rticles/djf500/200802221659DOWJONESDJONLINE000846_FORTUNE5.htm

Biotech News
AZhttp, Inc.
Biotechnology Marketing

Area to benefit from biotech industry

2008-02-26T07:59:00.000-08:00

Greenville Daily Reflector - Greenville,NC,USA "I think it's the largest
engine that can build the longer-term future of biotech, create new
companies," Dibner told a group of economic developers and ...

http://www.reflector.com/local/content/news/stories/2008/02/22/BioEast.html

See all stories on this topic:
http://news.google.com/news?hl=en&ncl=http://www.reflector.com/local/conten
t/news/stories/2008/02/22/BioEast.html

Biotech News
AZhttp, Inc.
Biotechnology Marketing

State increases bet that biotech can grow jobs

2008-02-25T08:40:00.000-08:00

State increases bet that biotech can grow jobs Charlotte Observer -
Charlotte,NC,USA Oliver Smithies, who joined UNC Chapel Hill in 1988, is one
of the NC Biotechnology Center's biggest success stories. The biotech
center, funded largely ...

http://www.charlotte.com/business/story/505579.html

See all stories on this topic:
http://news.google.com/news?hl=en&ncl=http://www.charlotte.com/business/sto
ry/505579.html

Biotech News
AZhttp, Inc.
Biotechnology Marketing

Arizona Biotech News

2008-02-22T12:23:00.001-08:00

Biotech News
AZhttp, Inc.
Biotechnology Marketing

UC Santa Barbara Students Against War

2008-02-22T11:07:00.000-08:00

UC Santa Barbara Students Against War Disrupt Army Biotech Conference By San
Francisco Bay Area Anti-war protesters celebrated on February 13th after
having forced the US Army's Institute for Collaborative Biotechnologies
(ICB) to cancel the second day of its annual conference at UC Santa Barbara.
The day prior, over 500 UCSB ...

http://www.indymedia.org/or/2008/07/900983.shtml

www.indymedia.org localfeatures features
http://www.indymedia.org/or/localfeatures-features-content.rss

Biotech News
AZhttp, Inc.
Biotechnology Marketing

Developing biotech

2008-02-22T08:28:00.000-08:00

By Rami Zurayk(Rami Zurayk)
"Farmers in 12 developing countries planted biotech crops in 2007, and for
the first time these countries outnumbered the industrialized countries
where such crops are grown, according to the report from the International
Service for ...

http://landandpeople.blogspot.com/2008/02/developing-biotech.html

Land and People
http://landandpeople.blogspot.com/

Biotech News
AZhttp, Inc.
Biotechnology Marketing

Worst Biotech Company in RTP

2008-02-22T08:23:00.000-08:00

If they don't serve food, you have to join, at least back in 2002 that was
still true, maybe it's changed now.

http://www.biofind.com/Rumor/Default.aspx?ID=143757

Biofind Rumor Mill Posts
http://www.biofind.com/

Biotech News
AZhttp, Inc.
Biotechnology Marketing

Feuerstein's Biotech-Stock Mailbag

2008-02-21T09:17:00.000-08:00

TheStreet.com - USA
It's been awhile since the last Biotech Mailbag, but this week's will be
devoted to DendreonDNDN! So warm up those keyboards, I await your hate mail.
...

http://www.thestreet.com/s/feuersteins-biotech-stock-mailbag/newsanalysis/t
echsoftware/10403744.html?puc=_googlen?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA

See all stories on this topic:
http://news.google.com/news?hl=en&ncl=http://www.thestreet.com/s/feuerstein
s-biotech-stock-mailbag/newsanalysis/techsoftware/10403744.html%3Fpuc%3D_goo
glen%3Fcm_ven%3DGOOGLEN%26cm_cat%3DFREE%26cm_ite%3DNA

Biotech News
AZhttp, Inc.
Biotechnology Marketing

Austin biotech company moving parts out of state

2008-02-20T08:39:00.000-08:00

Austin Herald -
Austin,MN,USA "At the present time, the business climate for drug producing
biotech companies, including a large number of experienced former Pfizer
employees who are ...

http://www.austindailyherald.com/articles/2008/02/16/news/news5.txt

See all stories on this topic:
http://news.google.com/news?hl=en&ncl=http://www.austindailyherald.com/arti
cles/2008/02/16/news/news5.txt

Biotech News
AZhttp, Inc.
Biotechnology Marketing